Description: Madison Investments, an investment advisor, released its “Madison Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The third quarter was difficult for the Small Cap Fund. The small-cap index’s performance was broad-based. The Madison Small Cap Fund (class Y) was down 1.3% in the quarter, significantly underperforming the […]

Description: Charles River Laboratories International recently presented at the Jefferies London Healthcare Conference 2025, following the release of its third quarter results that surpassed analyst expectations on revenue and adjusted EPS. Although the company outperformed on quarterly metrics, its decision to lower full-year GAAP EPS guidance has introduced new uncertainty about its near-term outlook. Given the company’s improved adjusted EPS but reduced annual guidance, we’ll explore how these mixed...

Description: Charles River Laboratories has continued to underperform the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Description: Charles River Laboratories is slated to lay off nearly 70 employees from its Wilmington facility. Here's what we know

Description: Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Description: WILMINGTON, Mass., November 17, 2025--Charles River Laboratories to Present at Jefferies Global Healthcare Conference

Description: Charles River Laboratories’ third quarter results were met with negative market reaction, as investors focused on the company’s muted top-line growth and margin pressures. Management cited ongoing challenges in the biotech funding environment, which dampened demand from smaller clients, and the loss of a major commercial customer in the Manufacturing segment. CEO James Foster explained that “client demand has stabilized,” but acknowledged lingering end market uncertainty, particularly among mid-

Description: In the past week, Charles River Laboratories International announced a major strategic overhaul following third-quarter results, including plans to divest underperforming businesses totaling about 7% of revenue, ramping up cost-saving measures expected to save US$70 million annually by 2026, and adopting a new US$1 billion share repurchase authorization. This move signals an accelerated effort to sharpen business focus and enhance shareholder value amid continued demand challenges and...

Description: Charles River Laboratories International (CRL) shares edged up slightly, with investors watching for updates that could guide the laboratory services provider's outlook. The stock has moved 1% higher over the past month, reflecting a modest uptick in sentiment. See our latest analysis for Charles River Laboratories International. Charles River Laboratories International's share price has experienced some volatility, rising nearly 15% over the past quarter, while the 1-year total shareholder...

Description: Lab services company Charles River Laboratories (NYSE:CRL) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.

Description: This morning, I am joined by James Foster, Chair, President, and Chief Executive Officer, and Mike Nell, Senior Vice President, Interim Chief Financial Officer, and Chief Accounting Officer. Following the presentation, they will respond to questions.

Description: Despite a slight revenue decline, CRL focuses on strategic initiatives and cost savings to drive long-term growth and shareholder value.

Description: Shares of lab services company Charles River Laboratories (NYSE:CRL) fell 5.8% in the morning session after the company reported third-quarter results that revealed significant underlying weaknesses.

Description: Charles River Laboratories International (CRL) said Wednesday it plans to sell certain underperformi

Description: While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.

Description: Charles River (CRL) delivered earnings and revenue surprises of +4.74% and +2.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Lab services company Charles River Laboratories (NYSE:CRL) announced better-than-expected revenue in Q3 CY2025, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.

Description: CRL) on Wednesday reported third-quarter profit of $54.4 million. The Wilmington, Massachusetts-based company said it had profit of $1.10 per share. Earnings, adjusted for non-recurring costs, came to $2.43 per share.

Description: WILMINGTON, Mass., November 05, 2025--Charles River Laboratories Provides Update on Strategic Review

Description: WILMINGTON, Mass., November 05, 2025--Charles River Laboratories Announces Third-Quarter 2025 Results

Description: Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results this Wednesday before market hours. Here’s what you need to know.

Description: Charles River Laboratories International has seen its Fair Value Estimate nudge higher, climbing by $1.00 to $186.87. Recent analyst research has driven this increase, citing industry stabilization and improving demand. However, there are also calls for caution as the company moves forward. Stay tuned to discover how investors can track future shifts in sentiment around this evolving stock story. Analyst Price Targets don't always capture the full story. Head over to our Company Report to...

Description: Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.

Description: Charles River Laboratories is all set to release its fiscal third-quarter earnings next month, and analysts project a low double-digit profit decline.

Description: In recent days, Charles River Laboratories International announced several new collaborations, including with The Francis Crick Institute to accelerate Antibody-Drug Conjugate development and with X-Chem to expand access to its proprietary DNA-encoded library platform for hit identification in drug discovery. These collaborations, along with the launch of a global Scientific Advisory Board for alternative testing methodologies, highlight Charles River's commitment to innovation in drug...

Description: WILMINGTON, Mass., October 22, 2025--Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.

Description: Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Description: meQuilibrium (meQ), the global leader in proactive workforce mental health and performance solutions, has announced the winners of its annual 2025 Resilience Awards, which honor exceptional HR leaders and organizations for their achievements in workforce well-being. The 2025 Resilience Champion of the Year was awarded to Roman Grubbs, Ph.D., Executive Director of Employee Experience & Analytics at Charles River Labs, for his work implementing successful well-being strategies that are working in

Description: WILMINGTON, Mass., October 20, 2025--Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics. This partnership enables Charles River clients to access X-Chem’s DEL platform, which features a proprietary library of over 15 billion compou